drugset / Trial / NCT03169790
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with with CD20-positive NHL who have progressed on or after rituximab therapy.
Timeline
- Start
- 2017-12
- Primary completion
- 2019-01
- Completion
- 2021-12-23
Outcome
Outcome not reported
Stopped: “Trial not initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | ETBX-061 | Vaccine | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Lovaza | Other / unclassified | — | — |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | haNK | Cell therapy | — | Intravenous |